Compare Enveric Biosciences Inc (ENVB) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Firy Inc. — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Firy Inc. trades at $11.73 (market cap $196.97M). The key difference: Firy Inc. is far larger — about 29.4× Enveric Biosciences Inc's market cap, and Firy Inc. is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Firy Inc. for 13 Days on average.
| ENVB | FIRY | |
|---|---|---|
Market Cap | $6.69M | $196.97M |
Volume | 41,141 | 155,239 |
Sector | Health | Technology |
52-Week High | $10.80 | $13.10 |
52-Week Low | $1.27 | $2.28 |
Typical Hold Time | 14 Days | 13 Days |
Enterprise Value | -$1.60M | $165.57M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, showing continued volatility amid its transition to a holding company structure. The stock maintains a bullish technical signal despite negative profitability metrics, with revenue stabilizing around $100M annually but net losses persisting. Recent developments include a $719M legal victory against Papaya Gaming and board additions, though cash burn remains elevated at -$86M in 2025.
The outlook remains speculative with significant execution risk. While the legal win provides potential upside, persistent losses and cash burn challenge near-term viability. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty around the company's ability to monetize assets and achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
